Imricor Advances Towards U.S. Market Entry with FDA Submission Imricor Medical Systems (ASX: IMR) is making steady progress in its regulatory journey, recently submitting the second module of its Premarket…
Opthea Publishes Phase 2b Wet AMD Study in Peer-Reviewed Journal
Opthea (ASX/NASDAQ: OPT) has announced the publication of new findings from its Phase 2b study on sozinibercept for wet age-related macular degeneration (wet AMD) in Ophthalmic Surgery, Lasers and Imaging…
Endeavour Group’s Half-Year Results: Stable Sales, Strong Cash Flow, and a Resilient Outlook
28 February 2025 – Endeavour Group (ASX: EDV) has delivered a steady first half for FY25, reporting $6.6 billion in sales, broadly in line with the previous year. While consumer…
Coles Delivers Resilient First-Half Results Amid Supply Chain Challenges
Coles Group has posted a solid set of numbers for the first half of FY25, with strong supermarket performance driving overall growth despite broader economic pressures. The company reported group…
Smartgroup Reports Strong 2024 Results with Growth Across Key Segments
Smartgroup Corporation (ASX: SIQ) has wrapped up 2024 with an impressive financial and operational performance, delivering 22% revenue growth to $305.8 million and a 15% rise in NPATA to $72.4…
Lynas Rare Earths Half-Year 2025 Results: Growth Amid Market Challenges
Lynas Rare Earths (ASX: LYC) has released its financial results for the first half of FY25, showing a solid increase in production and sales but facing profitability headwinds due to…
Viva Energy Reports $748.6M EBITDA for FY2024, Eyes Cost Reductions and Growth
Viva Energy Group Limited (ASX: VEA) has posted strong full-year results for 2024, with Group EBITDA (RC) rising 5% to $748.6 million, driven by solid growth in Commercial & Industrial…
Zip Co (ASX: ZIP) Reports Record H1 FY25 Earnings, Driven by U.S. Growth
Cash EBTDA More Than Doubles as Zip Strengthens Market Position Zip Co Limited (ASX: ZIP) has delivered a blockbuster first half for FY25, with cash EBTDA surging 117.1% to $67…
4DMedical Secures $5.5M Placement and Launches $7M Underwritten Share Purchase Plan
4DMedical Limited (ASX:4DX), a leader in respiratory imaging technology, has successfully raised $5.5 million through a share placement to institutional and sophisticated investors. The company is also launching a $7…
Paradigm Secures Ethics Approval for Phase 3 Knee Osteoarthritis Trial in Australia
Paradigm Biopharmaceuticals (ASX: PAR) has taken a major step forward in its mission to develop new treatments for osteoarthritis, securing centralised Human Research Ethics Committee (HREC) approval for its pivotal…